| Literature DB >> 26894600 |
Zare-Abdollahi Davood1, Safari Shamsi1, Hamid Ghaedi1, Riazi-Isfahani Sahand2, Ghadyani Mojtaba1, Tabarraee Mahdi1, Mirfakhraie Reza1, Mohammad Javad Ebrahimi1, Reyhaneh Sadat Miri-Moosavi3, Sara Boosaliki1, Omrani Mir Davood4.
Abstract
In acute myeloid leukemia (AML), despite the acceptance of standard intensive chemotherapy as an optimal induction regimen for all age groups, in the elderly patients, the best treatment should meet the challenge of multiple factors like age, comorbidities, and cytogenetics, making them ineligible for standard induction chemotherapy. Using the current low-intensity therapies like decitabine, azacitidine, and low-dose cytarabine as a single arm, outcomes for these patients remain poor. As a histone deacetylase inhibitor valproic acid (VPA) exhibit anticancer activity by triggering apoptosis, the mechanism of which is not yet completely clarified. To explore the possible connection between VPA treatment and the Hippo pathway as an apoptosis stimulating route, we also explore the expression of major components of this pathway and for the first time we postulate a relationship between VPA treatment and cell death induction through RASSF1A expression induction. Furthermore, we demonstrate that autophagy inhibition by chloroquine (CQ) significantly augmented the cytotoxic effect of VPA on AML cells, especially in those with unfavorable and normal karyotype. Regarding that VPA and CQ are well-tolerated drugs and our presumptive results of usefulness of VPA + CQ in three cytogenetic risk groups of AML, this combinatorial therapy could represent an attractive treatment option for older AML patients unfit for intensive therapy.Entities:
Keywords: AML; ATG7; Acute myeloid leukemia; Apoptosis; Autophagy; BECN1; Cytogenetics; HDAC; MST1; MST2; RASSF1A; VPA, chloroquine; Valproic acid
Mesh:
Substances:
Year: 2016 PMID: 26894600 DOI: 10.1007/s13277-016-4985-2
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283